MX9700309A - Antagonista de progesterona y gestageno para el tratamiento de endometriosis y leiomyomata uteri. - Google Patents

Antagonista de progesterona y gestageno para el tratamiento de endometriosis y leiomyomata uteri.

Info

Publication number
MX9700309A
MX9700309A MX9700309A MX9700309A MX9700309A MX 9700309 A MX9700309 A MX 9700309A MX 9700309 A MX9700309 A MX 9700309A MX 9700309 A MX9700309 A MX 9700309A MX 9700309 A MX9700309 A MX 9700309A
Authority
MX
Mexico
Prior art keywords
gestagen
endometriosis
treatment
progesterone antagonist
individual dosage
Prior art date
Application number
MX9700309A
Other languages
English (en)
Inventor
Klaus Stoeckemann
Kristof Chwalisz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of MX9700309A publication Critical patent/MX9700309A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere al uso de un producto que contiene en combinacion unidades de dosis individuales de antagonista de progesterona competente y unidades de dosificacion individuales de un gestageno que se administrará secuencialmente de forma oral (estando el antagonista de progesterona competente en cada unidad de dosis individual en cantidades que no son capaces de inducir el aborto) para producir un medicamento para usarse en el tratamiento de endometriosis o leiomyomata uteri.
MX9700309A 1994-07-27 1995-07-27 Antagonista de progesterona y gestageno para el tratamiento de endometriosis y leiomyomata uteri. MX9700309A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4426601A DE4426601A1 (de) 1994-07-27 1994-07-27 Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
PCT/EP1995/002998 WO1996003130A1 (de) 1994-07-27 1995-07-27 Progesteronantagonist und gestagen zur behandlung der endometriose und leiomyomata uteri

Publications (1)

Publication Number Publication Date
MX9700309A true MX9700309A (es) 1997-05-31

Family

ID=6524269

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700309A MX9700309A (es) 1994-07-27 1995-07-27 Antagonista de progesterona y gestageno para el tratamiento de endometriosis y leiomyomata uteri.

Country Status (22)

Country Link
US (1) US6043234A (es)
EP (1) EP0772441B1 (es)
JP (1) JPH10502092A (es)
KR (1) KR100365879B1 (es)
CN (1) CN1124848C (es)
AT (1) ATE213417T1 (es)
AU (1) AU705618B2 (es)
CA (1) CA2195425C (es)
CZ (1) CZ292177B6 (es)
DE (2) DE4426601A1 (es)
DK (1) DK0772441T3 (es)
ES (1) ES2172592T3 (es)
FI (1) FI970260A (es)
HU (1) HU226453B1 (es)
IS (1) IS4407A (es)
MX (1) MX9700309A (es)
NO (1) NO970309D0 (es)
NZ (1) NZ291417A (es)
PL (1) PL318264A1 (es)
PT (1) PT772441E (es)
SK (1) SK10497A3 (es)
WO (1) WO1996003130A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531936A1 (de) * 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
NZ504351A (en) 1997-11-14 2002-10-25 Akzo Nobel Nv Contraceptive kit comprising progestogen and anti-progestogen and use in treating bleeding induced by a progestogen-only contraceptive regimen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
JO2334B1 (en) * 2000-01-18 2006-06-28 باير شيرنغ فارما اكتنجيسيلشافت Drospirenone for hormone replacement therapy
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
US20080214512A1 (en) * 2007-03-01 2008-09-04 Christian Seitz Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation
DK2148681T3 (en) * 2007-04-20 2016-07-04 Preglem Sa Selective progesteronmodulatorer in the treatment of uterine bleeding
US20080306034A1 (en) * 2007-06-11 2008-12-11 Juneau Biosciences, Llc Method of Administering a Therapeutic
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE202011110355U1 (de) * 2011-03-09 2014-01-15 Arstat, Inc. Behandlung von Uterusmyomen durch intravaginale Verabreichung einer niedrigen Dosis eines selektiven Progesteronrezeptormodulators, eines Antigestagens oder eines Antigestagen-Wirkstoffes
BR112014029131B1 (pt) 2012-05-31 2021-03-09 Allergan Pharmaceuticals International Limited cápsula de mucoadesivo
CA2888377C (en) 2012-11-02 2021-02-02 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
HUE042368T2 (hu) 2013-04-11 2019-06-28 Bayer Pharma AG Progeszteronreceptor-antagonista dózisformája
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
US9603856B2 (en) * 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
FR3078952B1 (fr) * 2018-03-16 2020-03-27 Arianegroup Sas Systeme de mise en orbite de travail pour un satellite

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore

Also Published As

Publication number Publication date
AU705618B2 (en) 1999-05-27
ATE213417T1 (de) 2002-03-15
DK0772441T3 (da) 2002-05-27
FI970260A0 (fi) 1997-01-22
EP0772441A1 (de) 1997-05-14
DE4426601A1 (de) 1996-02-01
NO970309L (no) 1997-01-24
EP0772441B1 (de) 2002-02-20
FI970260A (fi) 1997-01-22
NZ291417A (en) 1998-12-23
CZ20797A3 (en) 1997-05-14
PL318264A1 (en) 1997-05-26
CN1154067A (zh) 1997-07-09
PT772441E (pt) 2002-08-30
CA2195425A1 (en) 1996-02-08
HUT77092A (hu) 1998-03-02
KR100365879B1 (ko) 2003-03-10
HU226453B1 (en) 2008-12-29
CA2195425C (en) 2008-03-11
CZ292177B6 (cs) 2003-08-13
SK10497A3 (en) 1997-08-06
WO1996003130A1 (de) 1996-02-08
DE59510069D1 (de) 2002-03-28
IS4407A (is) 1997-01-02
ES2172592T3 (es) 2002-10-01
AU3254395A (en) 1996-02-22
KR970704450A (ko) 1997-09-06
CN1124848C (zh) 2003-10-22
NO970309D0 (no) 1997-01-24
JPH10502092A (ja) 1998-02-24
US6043234A (en) 2000-03-28

Similar Documents

Publication Publication Date Title
MX9700309A (es) Antagonista de progesterona y gestageno para el tratamiento de endometriosis y leiomyomata uteri.
ATE217192T1 (de) Kombinationsprodukt zur kontrazeption enthaltend progesteronantagonisten und gestagenen
ES256592U (es) Recipiente de distribucion farmaceutico
UA41401C2 (uk) Фармацевтичний контрацептивний комбінований препарат
NZ234051A (en) Treating post-menopausal disorders using an estrogenic compound mixed with a compound having progestational activity
ATE239482T1 (de) Neue arzneiformulierung
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
BR9709934A (pt) Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
Buttram Jr Cyclic use of combination oral contraceptives and the severity of endometriosis
IL102032A0 (en) 2-amino-5-cyano-1,4-dihydropyridines,their preparation and pharmaceutical compositions containing them
HUP9901474A2 (hu) Szekvenciális ösztrogén/progeszteron-antagonista kombináció hormonhelyettesítő terápiához
König et al. Neuroleptics in the treatment of schizophrenia: have there been changes in the dosage regimen?
MXPA94000705A (es) Esteroides de estreno como iniciadores neuroquimicos del cambio en la funcion hipotalamica humana ycomposiciones farmaceuticas y metodos relacionados.
Manuilova et al. Systemic changes during the use of hormonal contraceptives
des Affaires Economiques Ministerial Order of 3 February 1989 designating certain products as medicines
GR3026094T3 (en) Orally administerable esters of 14 alpha,15 alpha-methylene-oestradiol with an oestrogenic action
UA36073A (uk) Спосіб лікування невиношування вагітності
TH14144EX (th) การลดการสูญเสียโลหิตแบบไหลออกที่เกิดจากการใช้โปรเกสทิน

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees